Benign prostate hyperplasia is the most common disease in the aging male, often comorbid with erectile dysfunction. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) decrease lower urinary tract symptoms in patients with erectile dysfunctionandBPH.WestudiedPDE5expression and activity in the human bladder and PDE5i effects both in vitro (human and rat) and in vivo (rat).PDE5is highly expressed in rat and human bladder and immunolocalized in vascular endotheliumandmusclefibers. Sildenafil, tadalafil,andvardenafil blocked 70% of the total cGMP-catabolizing activity; vardenafil was the most potent (IC50 0.3 nM). In human bladder cells and in rat strips, a PDE-resistant cGMP analog, SP-8-Br-PETcGMPS, induced, respectively, a consistent antiproliferative and relaxant effect. In contrast, the nitric oxide donor sodium nitroprusside (SNP) was almost ineffective. However, blocking PDE5 with vardenafil increased SNP antiproliferative and relaxant activity up to the level observed with SP-8-Br-PETcGMPS. We also found that castration decreased, and T supplementation restored, PDE5 gene expression in rat bladder. Accordingly, bladder strips from castrated rats were more sensitive to SNP-induced relaxation than strips from control or T-replaced rats, whereas in the presence of vardenafil, all groups showed the same SNP sensitivity. To discover whether vardenafil affects bladder activity in vivo, the rat bladder outlet obstruction model was used. Chronic treatment with 10 mg/kgd vardenafil significantly reduced nonvoiding contractions (47%, P < 0.05 vs. placebo) up to tamsulosin level (51%). Overall, these results demonstrate that PDE5 regulates bladder smooth muscle tone, strongly limiting the nitric oxide/cGMP signaling, and that vardenafil,byblockingPDE5,maybeapossible therapeutic option for bladder dysfunction by ameliorating irritative lower urinary tract symptoms. (Endocrinology 148: 1019–1029, 2007)

Characterization and functional role of androgen-dependent PDE5 activity in the bladder / FILIPPI S; MORELLI A; SANDNER P; FIBBI B; MANCINA R; MARINI M; GACCI M; VIGNOZZI L; VANNELLI GB; CARINI M; FORTI G; M. MAGGI. - In: ENDOCRINOLOGY. - ISSN 0013-7227. - STAMPA. - 148:(2007), pp. 1019-1029. [10.1210/en.2006-1079]

Characterization and functional role of androgen-dependent PDE5 activity in the bladder.

FILIPPI, SANDRA;MORELLI, ANNAMARIA;MANCINA, ROSA;MARINI, MIRCA;GACCI M;VIGNOZZI, LINDA;VANNELLI, GABRIELLA;CARINI, MARCO;FORTI, GIANNI;MAGGI, MARIO
2007

Abstract

Benign prostate hyperplasia is the most common disease in the aging male, often comorbid with erectile dysfunction. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) decrease lower urinary tract symptoms in patients with erectile dysfunctionandBPH.WestudiedPDE5expression and activity in the human bladder and PDE5i effects both in vitro (human and rat) and in vivo (rat).PDE5is highly expressed in rat and human bladder and immunolocalized in vascular endotheliumandmusclefibers. Sildenafil, tadalafil,andvardenafil blocked 70% of the total cGMP-catabolizing activity; vardenafil was the most potent (IC50 0.3 nM). In human bladder cells and in rat strips, a PDE-resistant cGMP analog, SP-8-Br-PETcGMPS, induced, respectively, a consistent antiproliferative and relaxant effect. In contrast, the nitric oxide donor sodium nitroprusside (SNP) was almost ineffective. However, blocking PDE5 with vardenafil increased SNP antiproliferative and relaxant activity up to the level observed with SP-8-Br-PETcGMPS. We also found that castration decreased, and T supplementation restored, PDE5 gene expression in rat bladder. Accordingly, bladder strips from castrated rats were more sensitive to SNP-induced relaxation than strips from control or T-replaced rats, whereas in the presence of vardenafil, all groups showed the same SNP sensitivity. To discover whether vardenafil affects bladder activity in vivo, the rat bladder outlet obstruction model was used. Chronic treatment with 10 mg/kgd vardenafil significantly reduced nonvoiding contractions (47%, P < 0.05 vs. placebo) up to tamsulosin level (51%). Overall, these results demonstrate that PDE5 regulates bladder smooth muscle tone, strongly limiting the nitric oxide/cGMP signaling, and that vardenafil,byblockingPDE5,maybeapossible therapeutic option for bladder dysfunction by ameliorating irritative lower urinary tract symptoms. (Endocrinology 148: 1019–1029, 2007)
2007
148
1019
1029
FILIPPI S; MORELLI A; SANDNER P; FIBBI B; MANCINA R; MARINI M; GACCI M; VIGNOZZI L; VANNELLI GB; CARINI M; FORTI G; M. MAGGI
File in questo prodotto:
File Dimensione Formato  
Endocrinology, 2007.pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 687.98 kB
Formato Adobe PDF
687.98 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/253716
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 203
  • ???jsp.display-item.citation.isi??? 186
social impact